Julian A. Symons - Mar 15, 2023 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Executive Vice President, Chief Scientific Officer
Signature
/s/ Lucinda Y. Quan, as attorney-in fact for Julian A. Symons
Stock symbol
ALGS
Transactions as of
Mar 15, 2023
Transactions value $
$0
Form type
4
Date filed
3/17/2023, 04:11 PM
Previous filing
Jul 11, 2022
Next filing
Sep 12, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +78.8K $0.00 78.8K Mar 15, 2023 Common Stock 78.8K $1.34 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Executive Vice President, Chief Scientific Officer